Holen Sie sich die Stockscreener-App
4.82
1.43%
-0.07
Handel nachbörslich:
4.81
-0.01
-0.21%
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
NFL voice, sports agent join webinar on head trauma, CTE, ALS - Stock Titan
COYA Maintains Buy Rating by Chardan Capital -- Price Target at $14 - GuruFocus
Coya Therapeutics (COYA) Gains 2.16% as Stock Nears Key Resistance ZoneDip Buy Trade - newsline.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Coya Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact - Yahoo Finance
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase - BioSpace
COYA Q1 2026 Earnings: EPS Surprises Wall Street with Narrower Loss, Stock DeclinesAnnual Financial Report - newsline.com
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Roth MKM Initiates Coya Therapeutics(COYA.US) With Buy Rating, Announces Target Price $12 - Moomoo
Roth/MKM initiates Coya Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Roth/MKM initiates Coya Therapeutics stock with buy rating - Investing.com
Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Coya Therapeutics (COYA) Surges 1.87% as Shares Approach Resistance ZoneStock Picks - newsline.com
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - BioSpace
COYA Q1 2026 Earnings: EPS Beat Provides Silver Lining as Revenue Remains AbsentEarnings Expansion Phase - The Legal Advocate
COYA Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances PipelineQuarterly Earnings - The Legal Advocate
COYA Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock Rises on Efficiency GainsGuidance vs Actual - The Legal Advocate
COYA | Coya Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Coya Therapeutics secures FDA fast track status for COYA 302 - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
Lake Street Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $17 - Moomoo
8-K: Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatemoomoo - Moomoo
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Chardan Capital Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
FDA puts injection therapy COYA 302 on fast track for treating ALS - ALS News Today
[ARS] Coya Therapeutics, Inc. SEC Filing - Stock Titan
Coya Therapeutics (COYA) 2026 proxy outlines director elections and auditor ratification - Stock Titan
Coya Therapeutics 1Q Research and Development Expenses $4.1 M >COYA - Moomoo
FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential - Streetwise Reports
Coya Therapeutics Announces $30 Million At-the-Market Offering Agreement with Leerink Partners - Minichart
Coya Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coya Therapeutics, Inc. Q1 2026 10-Q Filing: Financial Statements, Market Risks, and Legal Disclosures - Minichart
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of - pharmiweb.com
Coya Therapeutics Establishes $30 Million ATM Equity Program - TipRanks
Coya Therapeutics entered into sales agreement, may offer and sell from time to time shares of co's common stock for up to $30 million - marketscreener.com
Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million - TradingView
Coya Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Coya Therapeutics Updates Q1 Results, COYA 302 Progress - TipRanks
Coya Therapeutics (COYA) launches $30,000,000 at-the-market stock offering - Stock Titan
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Coya Therapeutics (COYA) launches $30M at‑the‑market equity program with Leerink - Stock Titan
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - BioSpace
Coya Therapeutics receives FDA fast track for ALS treatment By Investing.com - Investing.com Australia
Coya Therapeutics Reports Q1 2026 Financial Results, Highlights ALS and FTD Drug Progress and FDA Fast Track Designation - Minichart
Coya Therapeutics receives FDA fast track for ALS treatment - Investing.com
Coya Therapeutics, Inc. 1Q 2026: Revenue $0.25M, EPS $(0.32) — 10-Q Summary - TradingView
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Coya Therapeutics (NASDAQ: COYA) posts Q1 loss as COYA 302 wins FDA Fast Track - Stock Titan
Fast Track lifts Coya Therapeutics (NASDAQ: COYA) Q1 2026 biotech update - Stock Titan
TradingKey - TradingKey
Coya Therapeutics Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):